Primary information |
---|
ID | antitb_1916, |
Name | 27387357 |
N-Terminal modification | Peptide-1 |
C-Terminal Modification | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Amidation |
Length | A6c = 1-aminocyclohexane carboxylic acid, |
Chirality | Linear |
Nature | 22 |
Source | D |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC =4.92 μM |
Inhibition Concentration | In vitro |
Sequence | 2016 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Cell wall pore formation |
PMID | NA |
Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1927, |
Name | 27387357 |
N-Terminal modification | Peptide-1 |
C-Terminal Modification | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Amidation |
Length | A6c = 1-aminocyclohexane carboxylic acid, |
Chirality | Linear |
Nature | 22 |
Source | D |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis MDR |
Cell Line | MIC =4.92 μM |
Inhibition Concentration | In vitro |
Sequence | 2016 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Cell wall pore formation |
PMID | NA |
Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1938, |
Name | 27387357 |
N-Terminal modification | Peptide-1 |
C-Terminal Modification | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Amidation |
Length | A6c = 1-aminocyclohexane carboxylic acid, |
Chirality | Linear |
Nature | 22 |
Source | D |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis XDR |
Cell Line | MIC =4.92 μM |
Inhibition Concentration | In vitro |
Sequence | 2016 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | Cell wall pore formation |
PMID | NA |
Year of Publication | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus |
Tertiary Structure (Technique) | Not Predicted), |